AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8157711 — intervention group
Group type: EXPERIMENTAL
Intervention: Nal‐Glu plus T plus Teslac
Number of subjects: 3
Study 8157711 — intervention group
Group type: COMPARATOR
Intervention: Nal‐Glu plus T
Number of subjects: 3
Study 8157711 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 3
Study 3358810 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team care (T group)
Number of subjects: 59
Study 3358810 — intervention group
Group type: COMPARATOR
Intervention: Regular outpatient clinic care (NT group)
Number of subjects: 59
Study 31883845 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 140 mg (n = 46)
Number of subjects: 116
Study 31883845 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg (n = 41)
Number of subjects: 116
Study 31883845 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 29)
Number of subjects: 116
Study 31883845 — intervention group
Group type: COMPARATOR
Intervention: Brodalumab vs Ustekinumab (anti-IL-23/IL-12)
Number of subjects: 116
Study 30208344 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Health Nurse Consultant (PHNC) in addition to usual care
Number of subjects: 160
Study 30208344 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 160
Study 28012190 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalpel debridement
Number of subjects: 62
Study 28012190 — intervention group
Group type: COMPARATOR
Intervention: Salicylic acid patches (Callívoro Marthand®)
Number of subjects: 62
Study 26172283 — intervention group
Group type: EXPERIMENTAL
Intervention: FRC FPDs made with pre-impregnated glass or polyethylene fibre materials
Number of subjects: 120
Study 23329886 — intervention group
Group type: COMPARATOR
Intervention: Group C (tidal volume 8 ml/kg, frequency 12/min)
Number of subjects: 50
Study 23329886 — intervention group
Group type: EXPERIMENTAL
Intervention: Group L (tidal volume 6 ml/kg, frequency 16/min)
Number of subjects: 50
Study 21262922 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based order intervention
Number of subjects: 0
Study 21262922 — intervention group
Group type: COMPARATOR
Intervention: Control hospital
Number of subjects: 0
Study 21262922 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative antibacterials (treatment indication)
Number of subjects: 0
Study 18199726 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal mucosa cells (BMC) harvested at baseline and 3 days after baseline.
Number of subjects: 31
Study 18199726 — intervention group
Group type: COMPARATOR
Intervention: Leukocytes collected in heparin and EDTA.
Number of subjects: 31
Study 16600934 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (0.5 g . kg(‐1) . d(‐1))
Number of subjects: 26
Study 16600934 — intervention group
Group type: COMPARATOR
Intervention: Amino acid mixture (0.8 g . kg(‐1) . d(‐1))
Number of subjects: 26
Study 15000437 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 20
Study 15000437 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 20
Study 15000437 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Glyburide and Metformin
Number of subjects: 20
Study 11345687 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen lysinate solution (160 mg in 100 ml, twice a day for seven days)
Number of subjects: 120
Study 11345687 — intervention group
Group type: COMPARATOR
Intervention: Benzidamine hydrochloride (15 ml, twice a day for seven days)
Number of subjects: 120
Study 8773944 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 21
Study 8773944 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 21
Study 8773944 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 21
Study 1729854 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimobendan 5 mg daily
Number of subjects: 52
Study 1729854 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimobendan 10 mg daily
Number of subjects: 52
Study 1729854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 30537550 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical hematopoietic stem cell transplantation (haplo‐HSCT)
Number of subjects: 68
Study 30537550 — intervention group
Group type: COMPARATOR
Intervention: Continuous TKI with chemotherapy (nontransplant arm)
Number of subjects: 68
Study 30537550 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving complete remission (CR) at induction end
Number of subjects: 68
Study 30537550 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving major molecular response (MMR) at 3 months
Number of subjects: 68
Study 29898217 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ozenoxacin cream 1%
Number of subjects: 411
Study 29898217 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 411
Study 27028282 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 5145
Study 24557105 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure (CP) of 30 N
Number of subjects: 79
Study 24557105 — intervention group
Group type: COMPARATOR
Intervention: No cricoid pressure (CP)
Number of subjects: 79
Study 24557105 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure (CP)
Number of subjects: 79
Study 22150098 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (8 ounces daily for 1 month)
Number of subjects: 36
Study 22150098 — intervention group
Group type: COMPARATOR
Intervention: White wine (8 ounces daily for 1 month)
Number of subjects: 36
Study 20886510 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ(10) treatment (1200 mg/day for 60 days)
Number of subjects: 30
Study 17302514 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg intravenous iron sucrose
Number of subjects: 10
Study 17302514 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=5) without iron treatment
Number of subjects: 10
Study 15598664 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing techniques during interactive group-based orientation sessions
Number of subjects: 162
Study 15598664 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not explicitly detailed)
Number of subjects: 162
Study 11864795 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching intervention (n = 121)
Number of subjects: 245
Study 11864795 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (n = 124)
Number of subjects: 245
Study 11864795 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching intervention
Number of subjects: 245
Study 10435727 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulphan at 600 mg/m2 with cyclophosphamide alone (Group B)
Number of subjects: 23
Study 10435727 — intervention group
Group type: COMPARATOR
Intervention: Busulphan at 16 mg/kg with cyclophosphamide and ATG (Group A)
Number of subjects: 23
Study 10435727 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulphan at 600 mg/m2 (Group B)
Number of subjects: 23
Study 10435727 — intervention group
Group type: COMPARATOR
Intervention: Busulphan at 16 mg/kg (Group A)
Number of subjects: 23
Study 8574032 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd zeolite oral suspension (250 to 1500 mL; 6 to 60 micrograms of Gd+3/mL) administered before and after MRI
Number of subjects: 30
Study 8574032 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd zeolite oral suspension
Number of subjects: 30
Study 2278526 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ephedrine hydrochloride nasal douche
Number of subjects: 84
Study 2278526 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 84
Study 7428408 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg mianserin
Number of subjects: 47
Study 7428408 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg mianserin
Number of subjects: 47
Study 7428408 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sustained-release amitriptyline
Number of subjects: 47
Study 30776522 — intervention group
Group type: EXPERIMENTAL
Intervention: CM‐OIT
Number of subjects: 41
Study 27862021 — intervention group
Group type: EXPERIMENTAL
Intervention: Objectifying task (manual/computer)
Number of subjects: 0
Study 27862021 — intervention group
Group type: COMPARATOR
Intervention: Non-objectifying task
Number of subjects: 0
Study 27862021 — intervention group
Group type: COMPARATOR
Intervention: Baseline condition
Number of subjects: 0
Study 26387891 — intervention group
Group type: EXPERIMENTAL
Intervention: LBNP (‐40 mmHg)
Number of subjects: 18
Study 26387891 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress (serial subtraction)
Number of subjects: 18
Study 26387891 — intervention group
Group type: EXPERIMENTAL
Intervention: COMBO (LBNP+mental stress)
Number of subjects: 18
Study 24488838 — intervention group
Group type: EXPERIMENTAL
Intervention: AN-EXRP
Number of subjects: 32
Study 24488838 — intervention group
Group type: COMPARATOR
Intervention: CRT
Number of subjects: 32
Study 22753648 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study 22753648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19827484 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied hydrogel containing 0.5% morphine plus subcutaneous placebo infusion
Number of subjects: 9
Study 19827484 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel plus subcutaneous infusion of 5mg morphine
Number of subjects: 9
Study 19827484 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel plus subcutaneous placebo infusion
Number of subjects: 9
Study 17201543 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaders high in SDO partnered with an agreeable follower (confederate)
Number of subjects: 4
Study 17201543 — intervention group
Group type: EXPERIMENTAL
Intervention: Followers high in RWA
Number of subjects: 4
Study 17201543 — intervention group
Group type: EXPERIMENTAL
Intervention: High SDO leader - high RWA follower dyads
Number of subjects: 4
Study 17201543 — intervention group
Group type: COMPARATOR
Intervention: Leaders low in SDO
Number of subjects: 4
Study 17201543 — intervention group
Group type: COMPARATOR
Intervention: Followers low in RWA
Number of subjects: 4
Study 15451907 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes and no heart failure (group 2, n = 107)
Number of subjects: 922
Study 15451907 — intervention group
Group type: EXPERIMENTAL
Intervention: No diabetes and heart failure (group 3, n = 247)
Number of subjects: 922
Study 15451907 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure history with no diabetes (group 5, n = 41)
Number of subjects: 922
Study 15451907 — intervention group
Group type: COMPARATOR
Intervention: No diabetes and no heart failure (group 1, n = 324)
Number of subjects: 922
Study 15451907 — intervention group
Group type: COMPARATOR
Intervention: Diabetes and heart failure (group 4, n = 183)
Number of subjects: 922
Study 15451907 — intervention group
Group type: COMPARATOR
Intervention: Heart failure history with diabetes (group 6, n = 20)
Number of subjects: 922
Study 11528307 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ECT (BL)
Number of subjects: 84
Study 11528307 — intervention group
Group type: COMPARATOR
Intervention: Right Unilateral ECT (RUL)
Number of subjects: 84
Study 9626795 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (600 mg/m2) and Cyclophosphamide (1,500 mg/m2) with filgrastim
Number of subjects: 27
Study 9626795 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin (300 mg/m2) and Cyclophosphamide (600 mg/m2) without filgrastim
Number of subjects: 27
Study 9626795 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin and Cyclophosphamide at 2.5 times standard dose with filgrastim
Number of subjects: 27
Study 9626795 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin and Cyclophosphamide at standard dose without filgrastim
Number of subjects: 27
Study 9626795 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin and Cyclophosphamide at 2.5 times standard dose
Number of subjects: 27
Study 9626795 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin and Cyclophosphamide after first cycle
Number of subjects: 27
Study 9626795 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin and Cyclophosphamide after fourth cycle
Number of subjects: 27
Study 8055283 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional brachytherapy
Number of subjects: 0
Study 8055283 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic brachytherapy with radiolabeled antibodies
Number of subjects: 0
Study 8055283 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality therapy
Number of subjects: 0
Study 3126626 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 20
Study 3126626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30772342 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac suppositories (50 mg) + Sublingual isosorbide dinitrate (5 mg)
Number of subjects: 886
Study 30772342 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac suppositories (50 mg)
Number of subjects: 886
Study 28224713 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet behavioral weight loss (IBWL)
Number of subjects: 136
Study 28224713 — intervention group
Group type: COMPARATOR
Intervention: Control (community campaign alone)
Number of subjects: 136
Study 25801162 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (0.3 mg/kg) with midazolam (0.02 mg/kg) and fentanyl (1 μg/kg)
Number of subjects: 97
Study 25801162 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.02 mg/kg) and fentanyl (1 μg/kg) with placebo (0.9% sodium chloride)
Number of subjects: 97
Study 25801162 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (K and C)
Number of subjects: 97
Study 23686563 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/day elemental iron supplements
Number of subjects: 60
Study 23686563 — intervention group
Group type: COMPARATOR
Intervention: 50 mg/day elemental iron + 500 mg/day ascorbic acid
Number of subjects: 60
Study 22080318 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat chocolate milk (1 g carbohydrate per kg body weight)
Number of subjects: 13
Study 22080318 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat chocolate milk
Number of subjects: 13
Study 22080318 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-electrolyte beverage (CE)
Number of subjects: 13
Study 19109447 — intervention group
Group type: EXPERIMENTAL
Intervention: Lokomat robotic-assisted gait training
Number of subjects: 63
Study 19109447 — intervention group
Group type: COMPARATOR
Intervention: Conventional gait training
Number of subjects: 63
Study 17407641 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g paracetamol plus 130 mg caffeine
Number of subjects: 320
Study 17407641 — intervention group
Group type: COMPARATOR
Intervention: 1 g paracetamol alone
Number of subjects: 320
Study 17407641 — intervention group
Group type: COMPARATOR
Intervention: 130 mg caffeine alone
Number of subjects: 320
Study 17407641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 15893088 — intervention group
Group type: EXPERIMENTAL
Intervention: <HS degree
Number of subjects: 0
Study 15893088 — intervention group
Group type: COMPARATOR
Intervention: At least a college degree
Number of subjects: 0
Study 12369656 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg once daily
Number of subjects: 1021
Study 12369656 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg once daily
Number of subjects: 1021
Study 12369656 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily
Number of subjects: 1021
Study 12369656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1021
Study 9647338 — intervention group
Group type: EXPERIMENTAL
Intervention: tolrestat (200 mg a day)
Number of subjects: 35
Study 9647338 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 35
Study 8090462 — intervention group
Group type: EXPERIMENTAL
Intervention: FASTPAC threshold strategy
Number of subjects: 135
Study 8090462 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard threshold strategy
Number of subjects: 135
Study 8090462 — intervention group
Group type: COMPARATOR
Intervention: Suprathreshold screening strategy
Number of subjects: 135
Study 2582720 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin infusion at a rate of 2 i.u./h for 1 h, followed by 4 i.u./h for a further hour
Number of subjects: 14
Study 2582720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2582720 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin infusion
Number of subjects: 14
Study 1101845 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 23
Study 31872791 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual intervention
Number of subjects: 120
Study 31872791 — intervention group
Group type: EXPERIMENTAL
Intervention: Group intervention
Number of subjects: 120
Study 31872791 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 120
Study 29843627 — intervention group
Group type: EXPERIMENTAL
Intervention: Placenta praevia/accreta
Number of subjects: 20017
Study 29843627 — intervention group
Group type: EXPERIMENTAL
Intervention: Caesarean section
Number of subjects: 20017
Study 29843627 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers in Asia
Number of subjects: 20017
Study 28011260 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard FLS training platform with medical-grade consumables (S-FLS)
Number of subjects: 39
Study 28011260 — intervention group
Group type: COMPARATOR
Intervention: Low-cost platform with training-grade products (LC-FLS)
Number of subjects: 39
Study 28011260 — intervention group
Group type: COMPARATOR
Intervention: Low-cost platform consumables (LC-FLS)
Number of subjects: 39
Study 25527758 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of multivitamins
Number of subjects: 37193
Study 25527758 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated multivitamin use during follow-up
Number of subjects: 37193
Study 23189924 — intervention group
Group type: EXPERIMENTAL
Intervention: Negotiated treatment plan
Number of subjects: 324
Study 23189924 — intervention group
Group type: COMPARATOR
Intervention: No negotiated treatment plan
Number of subjects: 324
Study 23189924 — intervention group
Group type: COMPARATOR
Intervention: Negotiated treatment plan at fewer than three time points
Number of subjects: 324
Study 21241290 — intervention group
Group type: EXPERIMENTAL
Intervention: MgCl(2) 2.5 g daily
Number of subjects: 106
Study 21241290 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inactive solution)
Number of subjects: 106
Study 18055171 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic anticoagulation with intravenous heparin
Number of subjects: 115
Study 18055171 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulation
Number of subjects: 115
Study 16585320 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) at 30-45 seconds
Number of subjects: 72
Study 16585320 — intervention group
Group type: COMPARATOR
Intervention: Immediate cord clamping (ICC) at 5-10 seconds
Number of subjects: 72
Study 12837899 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of North American Guidelines for Children's Agricultural Tasks (NAGCAT)
Number of subjects: 450
Study 12837899 — intervention group
Group type: EXPERIMENTAL
Intervention: High parental knowledge of child development
Number of subjects: 450
Study 9706914 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.25 mg/kg
Number of subjects: 31
Study 9706914 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution (control)
Number of subjects: 31
Study 8576291 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition
Number of subjects: 86
Study 8576291 — intervention group
Group type: COMPARATOR
Intervention: Fluid therapy
Number of subjects: 86
Study 2774145 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral intercostal nerve blocks (Group 1, 12 patients)
Number of subjects: 36
Study 2774145 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpleural catheter with local anaesthetic immediately after surgery (Group 2, 12 patients)
Number of subjects: 36
Study 2774145 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpleural catheter with local anaesthetic at three hours (Group 3, 12 patients)
Number of subjects: 36
Study 2774145 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of catheter 'top‐ups' between six and 18 hours after surgery
Number of subjects: 36
Study 708810 — intervention group
Group type: EXPERIMENTAL
Intervention: 120dB tones
Number of subjects: 64
Study 708810 — intervention group
Group type: EXPERIMENTAL
Intervention: 120dB fast rise-time tones
Number of subjects: 64
Study 30530342 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinning controller design algorithm for PBN stabilization
Number of subjects: 0
Study 30530342 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinning nodes selected for control inputs
Number of subjects: 0
Study 26951796 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult patients' vignettes
Number of subjects: 74
Study 24677033 — intervention group
Group type: EXPERIMENTAL
Intervention: HQK-1001 (2,2-dimethylbutyrate) at 15 mg/kg twice daily for 48 weeks
Number of subjects: 76
Study 24677033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 24677033 — intervention group
Group type: EXPERIMENTAL
Intervention: HQK-1001
Number of subjects: 76
Study 22952648 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (20-25% fat)
Number of subjects: 771
Study 22952648 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (40-45% fat)
Number of subjects: 771
Study 22952648 — intervention group
Group type: EXPERIMENTAL
Intervention: Replication study (8-week diet of 880 kcal/d and 20% fat)
Number of subjects: 771
Study 22952648 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist reduction
Number of subjects: 771
Study 19442592 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cycle exercise program with non-invasive ventilation (NIV)
Number of subjects: 16
Study 19442592 — intervention group
Group type: COMPARATOR
Intervention: Home-based cycle exercise program without non-invasive ventilation (NIV)
Number of subjects: 16